Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges

Detalhes bibliográficos
Autor(a) principal: Faro-Viana, João
Data de Publicação: 2022
Outros Autores: Bergman, Marie-Louise, Gonçalves, Lígia A., Duarte, Nadia, Coutinho, Teresa P., Borges, Patricia C., Diwo, Christian, Castro, Rute, ..., Nunes, Telmo, et al.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.5/24815
Resumo: ABSTRACT: While mRNA vaccines are administrated worldwide in an effort to contain the COVID-19 pandemic, the heterogeneity of the humoral immune response they induce at the population scale remains unclear. Here, in a prospective, longitudinal, cohort-study, including 1245 hospital care workers and 146 nursing home residents scheduled for BNT162b2 vaccination, together covering adult ages from 19 to 99 years, we analyse seroconversion to SARS-CoV-2 spike protein and amount of spike-specific IgG, IgM and IgA before vaccination, and 3-5 weeks after each dose. We show that immunogenicity after a single vaccine dose is biased to IgG, heterogeneous and reduced with increasing age. The second vaccine dose normalizes IgG seroconversion in all age strata. These findings indicate two dose mRNA vaccines is required to reach population scale humoral immunity. The results advocate for the interval between the two doses not to be extended, and for serological monitoring of elderly and immunosuppressed vaccinees.
id RCAP_944df7619949d4a88c720bb1bf30593e
oai_identifier_str oai:www.repository.utl.pt:10400.5/24815
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str
spelling Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age rangesAntibody responseCOVID-19BNT162b2/Comirnaty vaccineABSTRACT: While mRNA vaccines are administrated worldwide in an effort to contain the COVID-19 pandemic, the heterogeneity of the humoral immune response they induce at the population scale remains unclear. Here, in a prospective, longitudinal, cohort-study, including 1245 hospital care workers and 146 nursing home residents scheduled for BNT162b2 vaccination, together covering adult ages from 19 to 99 years, we analyse seroconversion to SARS-CoV-2 spike protein and amount of spike-specific IgG, IgM and IgA before vaccination, and 3-5 weeks after each dose. We show that immunogenicity after a single vaccine dose is biased to IgG, heterogeneous and reduced with increasing age. The second vaccine dose normalizes IgG seroconversion in all age strata. These findings indicate two dose mRNA vaccines is required to reach population scale humoral immunity. The results advocate for the interval between the two doses not to be extended, and for serological monitoring of elderly and immunosuppressed vaccinees.Nature ResearchRepositório da Universidade de LisboaFaro-Viana, JoãoBergman, Marie-LouiseGonçalves, Lígia A.Duarte, NadiaCoutinho, Teresa P.Borges, Patricia C.Diwo, ChristianCastro, Rute...Nunes, Telmoet al.2022-07-11T17:06:22Z2022-01-102022-01-10T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.5/24815engFaro-Viana J, Bergman ML, Gonçalves LA, Duarte N, Coutinho TP, Borges PC, Diwo C, Castro R, Matoso P, Malheiro V [et al.]. 2022. Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges. Nature Communications, 13(1):140. DOI: https://doi.org/10.1038/s41467-021-27761-zhttps://doi.org/10.1038/s41467-021-27761-z2041-1723info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-03-06T14:54:29ZPortal AgregadorONG
dc.title.none.fl_str_mv Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges
title Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges
spellingShingle Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges
Faro-Viana, João
Antibody response
COVID-19
BNT162b2/Comirnaty vaccine
title_short Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges
title_full Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges
title_fullStr Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges
title_full_unstemmed Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges
title_sort Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges
author Faro-Viana, João
author_facet Faro-Viana, João
Bergman, Marie-Louise
Gonçalves, Lígia A.
Duarte, Nadia
Coutinho, Teresa P.
Borges, Patricia C.
Diwo, Christian
Castro, Rute
...
Nunes, Telmo
et al.
author_role author
author2 Bergman, Marie-Louise
Gonçalves, Lígia A.
Duarte, Nadia
Coutinho, Teresa P.
Borges, Patricia C.
Diwo, Christian
Castro, Rute
...
Nunes, Telmo
et al.
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório da Universidade de Lisboa
dc.contributor.author.fl_str_mv Faro-Viana, João
Bergman, Marie-Louise
Gonçalves, Lígia A.
Duarte, Nadia
Coutinho, Teresa P.
Borges, Patricia C.
Diwo, Christian
Castro, Rute
...
Nunes, Telmo
et al.
dc.subject.por.fl_str_mv Antibody response
COVID-19
BNT162b2/Comirnaty vaccine
topic Antibody response
COVID-19
BNT162b2/Comirnaty vaccine
description ABSTRACT: While mRNA vaccines are administrated worldwide in an effort to contain the COVID-19 pandemic, the heterogeneity of the humoral immune response they induce at the population scale remains unclear. Here, in a prospective, longitudinal, cohort-study, including 1245 hospital care workers and 146 nursing home residents scheduled for BNT162b2 vaccination, together covering adult ages from 19 to 99 years, we analyse seroconversion to SARS-CoV-2 spike protein and amount of spike-specific IgG, IgM and IgA before vaccination, and 3-5 weeks after each dose. We show that immunogenicity after a single vaccine dose is biased to IgG, heterogeneous and reduced with increasing age. The second vaccine dose normalizes IgG seroconversion in all age strata. These findings indicate two dose mRNA vaccines is required to reach population scale humoral immunity. The results advocate for the interval between the two doses not to be extended, and for serological monitoring of elderly and immunosuppressed vaccinees.
publishDate 2022
dc.date.none.fl_str_mv 2022-07-11T17:06:22Z
2022-01-10
2022-01-10T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.5/24815
url http://hdl.handle.net/10400.5/24815
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Faro-Viana J, Bergman ML, Gonçalves LA, Duarte N, Coutinho TP, Borges PC, Diwo C, Castro R, Matoso P, Malheiro V [et al.]. 2022. Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges. Nature Communications, 13(1):140. DOI: https://doi.org/10.1038/s41467-021-27761-z
https://doi.org/10.1038/s41467-021-27761-z
2041-1723
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Nature Research
publisher.none.fl_str_mv Nature Research
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1777302195420528640

Registros relacionados